Akeso, Inc. Enjoys Bright Prospects as Favored by the Capital Market
- 2020年04月24日 19:37:00
- テクノロジー
- JCN Newswire
- コメント
Efficient R&D Platform and Strong R&D Strength
The Company is dedicated to finding solutions to treat tumors and immunological diseases. It is generally known that it takes years to develop a new drug. However, the Company has over 20 drug development programs developed in-house though it has been established for only eight years. These programs include 12 antibodies in clinical-stage development, six bi-specific antibodies (two of which are at the clinical stage), and four antibodies with IND approvals from the Food and Drug Administration (FDA). Its product pipelines cover several major diseases, such as tumors, immunological diseases, and cardiovascular diseases. It is worth mentioning that the Company has developed all its programs in-house. In November 2015, the Company became the first China-based biotech company to out-license a fully internally discovered monoclonal antibody to a world-leading pharmaceutical company as it out-licensed its CTLA-4 monoclonal antibody drug candidate (AK107) to Merck for a total consideration of up to USD200 million.
The Company's strong R&D capability is indispensable from its end-to-end ACE Platform that possesses comprehensive, the most cutting-edge functionalities in developing therapeutic antibodies. The ACE Platform encompasses drug development and manufacturing and enables seamless technology transfer from drug discovery and CMC to manufacturing. Moreover, it holds strong internal manufacturing capacity that is compliant with GMP standards regulated by the NMPA, FDA and EMA. All drugs in the clinical stage are produced in the Company's proprietary facilities in line with GMP standards.
Prominent Advantages of Core Products, Favored by the Capital Market
The key to biopharmaceutical success lies in R&D strength and efficiency. The player who takes the lead to develop a drug and obtain approval for launch, and who can prove commercialization capabilities will gain competitive edges.
The Company has developed industry-leading drugs with the ACE Platform including its core products: PD-1/CTLA-4 bi-specific antibody (AK104) and PD-1 monoclonal antibody drug, Penpulimab (AK105). Its products also encompass AK101, a promising monoclonal antibody against autoimmune diseases, and AK102 that has high potential to become the first cardiovascular drug candidate against PCSK9 developed in China.
The Company has led the world in terms of the R&D of bi-specific antibodies. Bi-specific antibodies are deemed as a second-generation antibody therapy against tumors. With respect to the research on bi-specific antibodies, the Company possesses the unique bifunctional antibody technology, Tetrabody, making it one of the few bi-specific antibody platforms verified in both manufacturing and clinical stage. According to clinical observation, compared with the combined therapy of Nivolumab and Ipilimumab, AK104 has demonstrated better safety and efficacy. As of September 30, 2019, over 90 bi-specific antibodies were undergoing clinic trial. Nevertheless, no PD-(L)-based bi-specific antibodies had been approved for market launch. AK104 is the world's first bi-specific antibody drug that is in the clinical trial stage. It is expected that the first new drug application (NDA) of AK104 of the Company for treating cervical cancer will result in first-mover advantage.
AK105 of the Company is a monoclonal antibody currently in late-stage clinical development. PD-1 monoclonal antibody drugs are experiencing fierce competition, as six PD-1 drugs have been launched in China. Despite the extensively competitive market, AK105 is still favored for its strong efficacy and high safety. Therefore, Sino Biopharmaceutical Limited, a HK-listed pharmaceutical leader, has cooperated with the Company to jointly develop and commercialize AK105. AK105 of the Company is the only PD-1 antibody that Sino Biopharm can use to develop PD-1-based monotherapy or combination therapy, which evidences the great commercial potential of AK105. After the new drug is launched, the wide online sale channels and immense commercial capability of Sino Biopharmaceutical Limited will be utilized by the Company to maximize the commercial value of AK105.
Thanks to its strong R&D strength and commercialization capabilities, the Company has been favored by the capital market. Through Series D financing in November last year, the Company raised USD126 million in total, with the leading investor being Sino Biopharmaceutical Limited. Medical funds like Lake Bleu Capital, OrbiMed, and AIHC Capital participated in the financing. The Company's valuation reached USD836 million after Series D financing and became nearly 18 times as high as that after Series A financing of RMB330 million in just four years. Especially, Shenzhen Capital Group Co., Ltd. (SCGC), a leading venture capital firm in China that was co-founded by the Shenzhen Municipal Government and a group of private partners, participated in every series of financing. Relevant funds under K. Wah Group became a shareholder of Akeso in the series of financing before the IPO. This also means that K. Wah Group has set foot in the healthcare sector. Investment from famous capital holders reflect Akeso's bright future.
Copyright 2020 JCN Newswire. All rights reserved. www.jcnnewswire.com
中居正広氏、14年前に脳科学者が「女性におぼれて芸能界追放」と“予言” X騒然「すごい」
大下容子アナ「自らを戒めてまいります」フジテレビに対する総務省の行政指導めぐりコメント
おじいちゃんとおばあちゃんが遊びに来た→犬が大慌てでお迎えして…あまりにも平和な『素敵すぎるやり取り』が71万再生「取り合い可愛いw」
カンテレ大多亮社長、4日午後にマスコミ緊急対応 中居正広氏めぐるトラブル当時、フジ専務
東国原英夫氏「マジか!ショック!」食道がん公表の石橋貴明にエール
教え子にわいせつ行為か 容疑で学習塾元教室長の30歳逮捕 東京
韓国・尹錫悦氏の弁護団「政治的な決定だ」 罷免決定に強く反発
Snow Man初ベストアルバムがサブスク解禁 5年間の歩みが詰まった全61曲 4・7配信
石橋貴明、食道がん公表から一夜明けTBSラジオ番組「石橋貴明は絶対に帰ってきます!!」
ドジャース名物リポーターが大谷翔平のずぶ濡れショット公開「忘れられないウイーク!」
多部未華子(30)結婚の裏事情あまりにも恐ろしすぎると話題に!
「中居正広」Xトレンド入り、第三者委員会の調査報告書にツッコミ殺到「こりゃ酷い」の声
中居正広氏、14年前に脳科学者が「女性におぼれて芸能界追放」と“予言” X騒然「すごい」
二階堂ふみが結婚!?お相手が衝撃的過ぎてネット民「マジか・・・」
有吉弘行、「感謝祭」で永野芽郁に暴走突撃の江頭2:50について“たったひと言”で言及
笠井信輔アナ、飲食店で隣席の女性に叱責され謝ったのに「自らのストレスを他人に向けて…」
「もう会えなくなるけど、こんな女がいたことも忘れないでね」ヒコロヒー“永久出禁”受け吐露
伝説のロックバンドドラマー、中居正広氏めぐるテレビ番組報道に「ハッキリ言います!」
日清食品どん兵衛CM、「アンミカ起用」で不買運動の動き
中居正広氏「ひと段落かな」B氏「動きます」女性A退職時の文面公開されX「最悪」「ヘド出る」
多部未華子(30)結婚の裏事情あまりにも恐ろしすぎると話題に!
二階堂ふみが結婚!?お相手が衝撃的過ぎてネット民「マジか・・・」
堀江貴文氏、炎上ストリートピアノ騒動に“たった5文字”で反応しX賛同多数
「中居正広」Xトレンド入り、第三者委員会の調査報告書にツッコミ殺到「こりゃ酷い」の声
楽しんご、銭湯での男性へのわいせつ行為で逮捕された中孝介容疑者に“8文字”でずばり私見
中居正広氏、14年前に脳科学者が「女性におぼれて芸能界追放」と“予言” X騒然「すごい」
【おすすめアニメ50選】完結済み!定番から最新作まで!
万引き逮捕の米田哲也容疑者を「ご親族かどなたか助けてあげられないのか」紀藤正樹氏「悲しい」
堺正章が60歳タレントと“禁断の”共演「確かに昔干したよ」「本気でした」激白しスタジオ騒然
【ネタバレ?】史実で見るキングダムの今後の展開まとめ〜中華統一までの全体像

中居正広氏、14年前に脳科学者が「女性におぼれて芸能界追放」と“予言” X騒然「すごい」
大下容子アナ「自らを戒めてまいります」フジテレビに対する総務省の行政指導めぐりコメント
おじいちゃんとおばあちゃんが遊びに来た→犬が大慌てでお迎えして…あまりにも平和な『素敵すぎるやり取り』が71万再生「取り合い可愛いw」
カンテレ大多亮社長、4日午後にマスコミ緊急対応 中居正広氏めぐるトラブル当時、フジ専務
東国原英夫氏「マジか!ショック!」食道がん公表の石橋貴明にエール
教え子にわいせつ行為か 容疑で学習塾元教室長の30歳逮捕 東京
韓国・尹錫悦氏の弁護団「政治的な決定だ」 罷免決定に強く反発
Snow Man初ベストアルバムがサブスク解禁 5年間の歩みが詰まった全61曲 4・7配信
石橋貴明、食道がん公表から一夜明けTBSラジオ番組「石橋貴明は絶対に帰ってきます!!」
ドジャース名物リポーターが大谷翔平のずぶ濡れショット公開「忘れられないウイーク!」